levodopa - CISMeF

Preferred Label : levodopa;

MeSH definition : The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.;

MeSH synonym : l 3,4 dihydroxyphenylalanine; l-dopa; l dopa; 3-hydroxy-l-tyrosine; 3 hydroxy l tyrosine; l-3,4-dihydroxyphenylalanine;

CISMeF synonym : medphano brand of levodopa; roberts brand of levodopa; roche brand of levodopa;

MeSH hyponym : larodopa; dopar; dopaflex; levopa;

Wikipedia link : https://en.wikipedia.org/wiki/L-DOPA;

Is substance : O;

UNII : 46627O600J;

InChIKey : WTDRDQBEARUVNC-LURJTMIESA-N;

Details

Origin ID

D007980;

UMLS CUI

C0023570;

ATC code(s)
- levodopa and decarboxylase inhibitor [ATC Code]
ATC code(s)
- levodopa [ATC Code]
- levodopa and decarboxylase inhibitor [ATC Code]
- levodopa, decarboxylase inhibitor and comt inhibitor [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Dihydroxyphenylalanine (substance) [SNOMED CT concept]
- dihydroxyphenylalanine [Substance BNPC]
- dihydroxyphenylalanine [SNOMED Notion]
- dopa [SNOMED Notion]
CISMeF manual mappings
- Levodopa adverse reaction (disorder) [SNOMED CT concept]
- Poisoning caused by levodopa (disorder) [SNOMED CT concept]
Indexing information
- levodopa 2,2-dimethylcyclopentyl ester [MeSH Supplementary Concept]
- levodopa cyclohexyl ester [MeSH Supplementary Concept]
- levodopa cyclopentyl ester [MeSH Supplementary Concept]
Pharmacological action(s)
- antiparkinson agents [MeSH Descriptor]
- dopamine agents [MeSH Descriptor]
Record concept(s)
- dopaflex [MeSH concept]
- dopar [MeSH concept]
- larodopa [MeSH concept]
- levodopa [MeSH concept]
- levopa [MeSH concept]
Related MeSH Supplementary Concept(s)
- ((O,O-diacetyl)-L-dopa-methylester)succinyldiamide [MeSH Supplementary Concept]
- (O,O-diacetyl)-L-Dopa-methylester fumaric diamide [MeSH Supplementary Concept]
- (O,O-diacetyl)-L-Dopa-methylester maleic diamide [MeSH Supplementary Concept]
- 3,4-dihydroxyphenylalanine 3-O-sulfate [MeSH Supplementary Concept]
- 3,4-dihydroxyphenylalanine 4-O-sulfate [MeSH Supplementary Concept]
- 4-(2-acetamido-3-ethoxy-3-oxopropyl)-1,2-phenylene diacetate [MeSH Supplementary Concept]
- 5-S-glutathionyl-beta-alanyl-L-DOPA [MeSH Supplementary Concept]
- 5-hydroxy-2-iodotyrosine [MeSH Supplementary Concept]
- ACS 84 [MeSH Supplementary Concept]
- Ac-LD(Ac)2-Gly-Pro-Glu(OMe)-OMe [MeSH Supplementary Concept]
- Atremorine [MeSH Supplementary Concept]
- BL-1023 [MeSH Supplementary Concept]
- L-3,4-(dioxyphenylacetyl)phenylalanine [MeSH Supplementary Concept]
- L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine [MeSH Supplementary Concept]
- L-DOPA-glucoside [MeSH Supplementary Concept]
- Stalevo [MeSH Supplementary Concept]
- benserazide, levodopa drug combination [MeSH Supplementary Concept]
- carbidopa, levodopa drug combination [MeSH Supplementary Concept]
- desoxyfructo-L-DOPA [MeSH Supplementary Concept]
- etilevodopa [MeSH Supplementary Concept]
- isopropyl 2-(2-amino-2-methylpropanamido)-3-(3,4-dihydroxyphenyl)propanoate [MeSH Supplementary Concept]
- levodopa 2,2-dimethylcyclopentyl ester [MeSH Supplementary Concept]
- levodopa 4-hydroxybutyl ester [MeSH Supplementary Concept]
- levodopa butyl ester [MeSH Supplementary Concept]
- levodopa cyclohexyl ester [MeSH Supplementary Concept]
- levodopa cyclopentyl ester [MeSH Supplementary Concept]
- levodopa ethylester [MeSH Supplementary Concept]
- levodopa isopropyl ester [MeSH Supplementary Concept]
- levodopa methyl ester [MeSH Supplementary Concept]
- levodopa-2,6-dimethyl-beta-cyclodextrin [MeSH Supplementary Concept]
- pyroglutamyl-L-DOPA-proline [MeSH Supplementary Concept]
- sirio [MeSH Supplementary Concept]
See also
- dopamine [MeSH Descriptor]
See also inter- (CISMeF)
- Product containing levodopa (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Biologically Active Substance [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- L-dopa [LOINC component]
- Levodopa [Substance BNPC]
- Levodopa [Vue CIM-11]
- Levodopa [NCIt concept]
- Levodopa [LOINC component]
- Product containing levodopa (medicinal product) [SNOMED CT concept]
- levodopa [ATC Code]
- levodopa [SNOMED Notion]
Validated automatic mappings to BTNT
- levodopa [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients